Method for treating neurodegenerative diseases

• US 9,949,943 B2
• Filed: 03/15/2017
• Issued: 04/24/2018
• Est. Priority Date: 07/26/2012
• Status: Active Grant

• Current Assignee: The William M. Yarbrough Foundation
• Original Assignee: The William M. Yarbrough Foundation
• Inventors: Silver, Michael E.
• Primary Examiner(s): Henley, III, Raymond J
• Application Number:
  US15/459,822
• Publication Number:
  US 20170181996A1
• Time in Patent Office: 405 Days
• Field of Search: 514562
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/26 Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00

Abstract

A method for treating neurodegenerative diseases including the step of administering an isothiocyanate functional surfactant to an area affected by a neurodegenerative disease, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

Claims

1. A method for treating a neurodegenerative disease, comprising the step(s) of:

administering a surfactant or a pharmaceutically acceptable salt thereof to an area affected by a neurodegenerative disease, wherein the protonated form of the surfactant is represented by the following chemical structure;

4. The method for treating the neurodegenerative disease according to claim 1, further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.

5. The method for treating the neurodegenerative disease according to claim 1, wherein the neurodegenerative disease is selected from at least one of the group comprising an amyloid-related disease, dementia, and Alzheimer'"'"'s disease.

2. A method for treating a neurodegenerative disease, comprising the step(s) of:

administering a surfactant or a pharmaceutically acceptable salt thereof to an area affected by a neurodegenerative disease, wherein the protonated form of the surfactant is represented by the following chemical structure;

6. The method for treating the neurodegenerative disease according to claim 2, further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.

7. The method for treating the neurodegenerative disease according to claim 2, wherein the neurodegenerative disease is selected from at least one of the group comprising an amyloid-related disease, dementia, and Alzheimer'"'"'s disease.

3. A method for treating a neurodegenerative disease, comprising the step(s) of:

administering a surfactant or a pharmaceutically acceptable salt thereof to an area affected by a neurodegenerative disease, wherein the protonated form of the surfactant is represented by the following chemical structure;

8. The method for treating the neurodegenerative disease according to claim 3, further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.

9. The method for treating the neurodegenerative disease according to claim 3, wherein the neurodegenerative disease is selected from at least one of the group comprising an amyloid-related disease, dementia, and Alzheimer'"'"'s disease.